This content is only available within our institutional offering.
21 Dec 2015
CCP-07 FDA filing remains on track for 2016
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
CCP-07 FDA filing remains on track for 2016
Vernalis’ cough cold product, CCP-07, has successfully completed a single-dose comparative bioavailability study and will now progress into a multiple-dose study. A potential FDA filing remains on track for 2016. We retain a Buy recommendation.